# A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)

> **NCT05494619** · PHASE3 · WITHDRAWN · sponsor: **Hoffmann-La Roche**

## Conditions studied

- Guillain-Barré Syndrome

## Interventions

- **DRUG:** Crovalimab
- **DRUG:** Placebo
- **DRUG:** Intravenous immunoglobulin therapy

## Key facts

- **NCT ID:** NCT05494619
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-11-30
- **Primary completion:** 2026-03-19
- **Final completion:** 2026-09-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study has been withdrawn due to an internal decision. The decision was not due to any safety concerns with study drug.
- **Last updated:** 2022-12-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05494619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05494619, "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05494619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*